Regeneron's (REGN) Dupilumab Receives FDA Breakthrough Designation; Roth Capital Comments
Tweet Send to a Friend
Roth Capital comments on Regeneron Pharmaceuticals (Nasdaq: REGN) following news that the U.S. Food and Drug Administration (FDA) has granted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
